Design, Synthesis and molecular docking study of hybrids of quinazolin-4(3H)-one as anticancer agents

ABSTRACT A series of 4-(2-(4-substituted phenyl)-4-oxoquinazolin-3(4H)-yl)-N-(2-(4-fluorophenyl)-4-oxo-5-(arylidene)thiazolidin-3-yl) benzamides (VIa-n) have been synthesized by condensation of N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-yl)-4-(4-oxo-2-(4-substituted phenyl)quinazolin-3(4H)-yl)benzamid...

Full description

Bibliographic Details
Main Authors: Sukanya Nara, Achaiah Garlapati
Format: Article
Language:English
Published: Facultad de Farmacia, Universidad de Granada
Series:Ars Pharmaceutica
Subjects:
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2340-98942018000300121&lng=en&tlng=en
_version_ 1818352259654746112
author Sukanya Nara
Achaiah Garlapati
author_facet Sukanya Nara
Achaiah Garlapati
author_sort Sukanya Nara
collection DOAJ
description ABSTRACT A series of 4-(2-(4-substituted phenyl)-4-oxoquinazolin-3(4H)-yl)-N-(2-(4-fluorophenyl)-4-oxo-5-(arylidene)thiazolidin-3-yl) benzamides (VIa-n) have been synthesized by condensation of N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-yl)-4-(4-oxo-2-(4-substituted phenyl)quinazolin-3(4H)-yl)benzamides (Va-b) with various aryl/heteroaryl aldehydes using conventional methodology. All compounds were screened for their in vitro anticancer activity against the human breast cancer cell lines (MCF-7), human lung cancer cell lines (A549) using MTT assay method and doxorubicin is used as standard drug. Compound VId, VIk and VIn showed high potency against A549 cell lines with IC50 values 0.035±0.002 µM, 0.031±0.002 µM and 0.030±0.002 µM respectively compared to 0.023±0.002 µM showed by the standard. However, highest activity against MCF-7 cell lines was exhibited by Va, Vb, VIk and VIn with IC50 values between 0.040 - 0.050 µM. All the remaining compounds showed moderate anticancer activity against both the MCF-7 and A549 cell lines. To understand the interactions with active binding site of receptor, molecular docking study was also performed.
first_indexed 2024-12-13T18:50:48Z
format Article
id doaj.art-491a6c3b399b4b478e8c5ed96e9de61d
institution Directory Open Access Journal
issn 2340-9894
language English
last_indexed 2024-12-13T18:50:48Z
publisher Facultad de Farmacia, Universidad de Granada
record_format Article
series Ars Pharmaceutica
spelling doaj.art-491a6c3b399b4b478e8c5ed96e9de61d2022-12-21T23:34:57ZengFacultad de Farmacia, Universidad de GranadaArs Pharmaceutica2340-989459312113110.30827/ars.v59i3.7360S2340-98942018000300121Design, Synthesis and molecular docking study of hybrids of quinazolin-4(3H)-one as anticancer agentsSukanya NaraAchaiah GarlapatiABSTRACT A series of 4-(2-(4-substituted phenyl)-4-oxoquinazolin-3(4H)-yl)-N-(2-(4-fluorophenyl)-4-oxo-5-(arylidene)thiazolidin-3-yl) benzamides (VIa-n) have been synthesized by condensation of N-(2-(4-fluorophenyl)-4-oxothiazolidin-3-yl)-4-(4-oxo-2-(4-substituted phenyl)quinazolin-3(4H)-yl)benzamides (Va-b) with various aryl/heteroaryl aldehydes using conventional methodology. All compounds were screened for their in vitro anticancer activity against the human breast cancer cell lines (MCF-7), human lung cancer cell lines (A549) using MTT assay method and doxorubicin is used as standard drug. Compound VId, VIk and VIn showed high potency against A549 cell lines with IC50 values 0.035±0.002 µM, 0.031±0.002 µM and 0.030±0.002 µM respectively compared to 0.023±0.002 µM showed by the standard. However, highest activity against MCF-7 cell lines was exhibited by Va, Vb, VIk and VIn with IC50 values between 0.040 - 0.050 µM. All the remaining compounds showed moderate anticancer activity against both the MCF-7 and A549 cell lines. To understand the interactions with active binding site of receptor, molecular docking study was also performed.http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2340-98942018000300121&lng=en&tlng=enQuinazolin-4 (3H) -onaThiazolidin-4-oneActividad anticancerosaAtraque molecular
spellingShingle Sukanya Nara
Achaiah Garlapati
Design, Synthesis and molecular docking study of hybrids of quinazolin-4(3H)-one as anticancer agents
Ars Pharmaceutica
Quinazolin-4 (3H) -ona
Thiazolidin-4-one
Actividad anticancerosa
Atraque molecular
title Design, Synthesis and molecular docking study of hybrids of quinazolin-4(3H)-one as anticancer agents
title_full Design, Synthesis and molecular docking study of hybrids of quinazolin-4(3H)-one as anticancer agents
title_fullStr Design, Synthesis and molecular docking study of hybrids of quinazolin-4(3H)-one as anticancer agents
title_full_unstemmed Design, Synthesis and molecular docking study of hybrids of quinazolin-4(3H)-one as anticancer agents
title_short Design, Synthesis and molecular docking study of hybrids of quinazolin-4(3H)-one as anticancer agents
title_sort design synthesis and molecular docking study of hybrids of quinazolin 4 3h one as anticancer agents
topic Quinazolin-4 (3H) -ona
Thiazolidin-4-one
Actividad anticancerosa
Atraque molecular
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S2340-98942018000300121&lng=en&tlng=en
work_keys_str_mv AT sukanyanara designsynthesisandmoleculardockingstudyofhybridsofquinazolin43honeasanticanceragents
AT achaiahgarlapati designsynthesisandmoleculardockingstudyofhybridsofquinazolin43honeasanticanceragents